相关临床试验
185
48 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
40
21.6%
已完成
97
52.4%
Enrolling By Invitation
1
0.5%
尚未招募
7
3.8%
招募中
26
14.1%
暂停
3
1.6%
终止
2
1.1%
撤回
9
4.9%
暂无批准数据
- Greater Manchester has secured £50 million from UKRI's Local Innovation Partnerships Fund to drive innovation-led growth across five major projects. - Two health-focused initiatives—the Greater Data Accelerator (£6.7M) and GM Wearables Cluster (£5.5M)—aim to accelerate medicines adoption and transform remote monitoring technologies. - The GROW AI project (£12.8M) will fast-track AI commercialisation and support SME adoption across the region, including health and life sciences applications. - The funding positions Greater Manchester as the first of 17 UK regions to move into full delivery under this flagship national programme.
- Over 4 million patients have already received faster lung cancer diagnoses or all-clears through AI-powered chest X-ray tools currently deployed in half of England's NHS trusts. - The UK government is investing £20 million to expand this proven AI technology to every NHS trust in England by 2029, with an additional £8.1 million for piloting six next-generation digital innovations. - Early data shows AI helps radiologists analyze scans in an average of 4 days compared to 8 days previously, enabling patients to begin treatment within the 62-day cancer waiting time standard. - Six new AI and digital technologies will be tested across 13 NHS sites targeting faster care for heart failure, stroke, lung cancer, lung infections, and tic disorders.
- Oscar Murphy, 28, became the first UK patient to receive obe-cel CAR-T therapy on the NHS at Manchester Royal Infirmary for B-cell acute lymphoblastic leukemia after his cancer returned following standard treatments. - Clinical trial data from the FELIX study showed 77% of patients achieved remission with obe-cel treatment, with half showing no signs of disease after three and a half years. - The therapy represents a breakthrough for aggressive blood cancers, offering patients years of survival compared to the typical six to eight months with conventional treatments. - NHS England will fund this personalized immunotherapy at several centers nationwide, with approximately 50 patients per year expected to benefit from the treatment.
- Three-year-old Oliver Chu became the first person globally to receive groundbreaking gene therapy for Hunter syndrome, a rare genetic disorder that typically causes death before age 20. - Nine months post-treatment, Oliver is producing hundreds of times the normal amount of the missing enzyme and showing dramatic improvements in speech, mobility, and cognitive development. - The Manchester-based trial involves five boys worldwide and represents a potential breakthrough for treating rare genetic conditions affecting over 3.5 million people in the UK. - The gene therapy uses modified stem cells to produce the missing iduronate-2-sulfatase enzyme, with modifications allowing it to cross the blood-brain barrier effectively.
- A new CAR-T therapy is being trialed in the UK as a potential cure for lupus, an autoimmune condition affecting approximately 69,000 people in the UK. - The trial, led by Professor Ben Parker at Manchester Royal Infirmary, aims to 'correct' the immune system using a method previously applied in blood cancer treatment. - Current lupus treatments involve lifelong immunosuppressants with varying effectiveness, highlighting the need for more effective and potentially curative therapies. - Early diagnosis and treatment are crucial for managing lupus, as prompt intervention can reduce the risk of long-term damage to affected organs.
